HDL-Lp-PLA2 is reduced in patients with combined hyperlipidemia, primary hypertriglyc-eridemia, pre-diabetes and metabolic syndrome[58,65] and is also independently associated with lower risk for cardiac death (Table 1)[66]. Here, PLA2G7 is linked to hyperlipidemia.